

Idiopathic Pulmonary: Consumption, Demand, Sales, Competitor and Forecast 2016 – 2021

*Idiopathic Pulmonary Global Market
2016 Analysis and Forecast to 2021*

PUNE, INDIA, November 4, 2016
/EINPresswire.com/ -- The IPF therapeutic market is currently dominated by the only two drugs that have gained marketing approval for IPF - Roche's Esbriet and Boehringer Ingelheim's Ofev. Esbriet was the first drug to gain approval for IPF in 2011 when it was approved for use in Europe, a full four years before rival Ofev. However, both gained approval into the largest IPF market of the US on the same day in October 2014.



WISE GUY
R E P O R T S

Norah Trent Partner Relations & Marketing Manager

✉ sales@wiseguyreports.com
☎ Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK)

🌐 <https://www.linkedin.com/company/4828928>
🐦 <https://twitter.com/WiseGuyReports>
📘 <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Wise.Guy.

Get Sample Report @ <https://www.wiseguyreports.com/sample-request/643852-opportunityanalyzer-idiopathic-pulmonary-fibrosis-forecast-to-2025>

The top-selling drug in IPF in value terms is Roche's Esbriet, which GlobalData estimates generated approximately \$572m in 2015 from the seven major markets. There is high R&D activity for the development of new therapies for IPF and eight promising therapies can potentially enter the market from 2015 to 2025. Numerous novel targets are being studied in the IPF pipeline, with major pharmaceutical players Roche, Sanofi, Bristol-Myers Squibb, and Biogen all active in the development process. Other promising pipeline candidates include FibroGen's CTGF inhibitor, Promedior's PTX2 protein, Afferent's P2X3 receptor antagonist, and MediciNova's 5-LO/LT pathway inhibitor. The continued uptake of Esbriet and Ofev, combined with the introduction of new novel drugs will shape the future competitive landscape and drive growth in the IPF market. Highlights Key Questions Answered - What was the impact of Esbriet and Ofev on the IPF market following their FDA approval in 2014 and what is their future outlook within this market? - What do physicians think about Esbriet and Ofev, and how they will be used for IPF during the forecast period? - What is the significance of late-phase pipeline products and how will their launch shape the future treatment landscape in IPF? - What are the unmet needs within the IPF market? - What are the remaining opportunities within the IPF market? Key Findings - The main drivers of growth for the IPF market include the increasing uptake of Esbriet and Ofev, the launch of new novel treatment options during the second half of the forecast period, and the increasing number of prevalent cases of IPF. - R&D strategies include the development of novel therapies, partnerships and acquisitions, combination of therapies, and targeting niche patient subpopulations. - The IPF therapeutic market is characterized by significant unmet needs. The most pressing unmet need is the development of a product capable of either stabilizing or reversing progression of IPF. Current therapies Esbriet and Ofev do not address this need and are only capable of slowing disease progression. - With high R&D activity in the IPF therapeutic market, physicians are looking forward to pipeline products becoming available, which will

enable them to improve patients' treatment. Scope - Overview of IPF, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current treatment options. - Annualized IPF therapeutic market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025. - Key topics covered include strategic competitor assessment, market characterization, unmet needs, and implications for the IPF therapeutics markets. - Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of mid-stage pipeline drugs. - Analysis of the current and future market competition in the global IPF therapeutics markets. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. Reasons to buy The report will enable you to - - Develop and design in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. - Develop business strategies by understanding the trends shaping and driving the global IPF therapeutic markets. - Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global IPF therapeutic markets in the future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Track drug sales in the global IPF therapeutic markets from 2015-2025. - Organize sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

| | | |
|-------|---|----|
| 1 | Table of Contents | 10 |
| 1.1 | List of Tables | 15 |
| 1.2 | List of Figures | 18 |
| 2 | Introduction | 19 |
| 2.1 | Catalyst | 19 |
| 2.2 | Related Reports | 20 |
| 3 | Disease Overview | 21 |
| 3.1 | Etiology and Pathophysiology | 24 |
| 3.1.1 | Etiology | 24 |
| 3.1.2 | Pathophysiology | 25 |
| 3.2 | Classification or Staging System | 28 |
| 3.3 | Prognosis | 31 |
| 3.4 | Quality of Life | 31 |
| 3.5 | Symptoms | 32 |
| 4 | Epidemiology | 34 |
| 4.1 | Disease Background | 34 |
| 4.2 | Risk Factors and Comorbidities | 34 |
| 4.3 | Global Trends | 36 |
| 4.3.1 | Incidence | 36 |
| 4.3.2 | Prevalence | 37 |
| 4.4 | Forecast | 39 |
| 4.4.1 | Sources Used | 39 |
| 4.4.2 | Forecast Assumptions and Methods | 44 |
| 4.4.3 | Sources Not Used | 51 |
| 4.5 | Epidemiological Forecast for IPF (2015-2025) | 52 |
| 4.5.1 | Diagnosed Incident Cases | 52 |
| 4.5.2 | Diagnosed Prevalent Cases | 60 |
| 4.5.3 | IPF Mortality | 67 |
| 4.6 | Discussion | 72 |
| 4.6.1 | Epidemiological Forecast Insight | 72 |
| 4.6.2 | Limitations of the Analysis | 73 |
| 4.6.3 | Strengths of the Analysis | 74 |
| 5 | Current Treatment Options | 75 |
| 5.1 | Overview | 75 |
| 5.2 | Product Profiles - Major Brands | 77 |
| 5.2.1 | Esbriet (Pirfenidone) | 77 |
| 5.2.2 | Ofev (Nintedanib) | 82 |
| 5.2.3 | Fluimucil (N-acetylcysteine) | 87 |
| 6 | Unmet Needs Assessment and Opportunity Analysis | 91 |
| 6.1 | Overview | 91 |
| 6.2 | Lack of an Efficacious Drug | 92 |
| 6.2.1 | Overview | 92 |
| 6.2.2 | Gap Analysis | 93 |
| 6.2.3 | Opportunity | 93 |
| 6.3 | Patient Access to Costly Treatments | 93 |
| 6.3.1 | Overview | 93 |
| 6.3.2 | Gap Analysis | 94 |
| 6.3.3 | Opportunity | 95 |
| 6.4 | Early and Prompt Diagnosis | 95 |
| 6.4.1 | Overview | 95 |
| 6.4.2 | Gap Analysis | 96 |
| 6.4.3 | Opportunity | 97 |
| 6.5 | Unrecognized Disease | 97 |
| 6.5.1 | | |

Access Report @ <https://www.wiseguyreports.com/reports/643852-opportunityanalyzer-idiopathic-pulmonary-fibrosis-forecast-to-2025>

Get in touch:

LinkedIn: www.linkedin.com/company/4828928

Twitter: <https://twitter.com/WiseGuyReports>

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.